'The
'We will also discuss opportunities we have to rapidly progress new treatments for emerging viral threats, and we welcome discussions with prospective commercial partners and collaborators,' said Dr
Island presentation details
Date & time: Tuesday 29 November at
Presenter: Dr
Presentation title: A repurposing antiviral solution for the prevention and treatment of Dengue
Contact:
info@islandpharmaceuticals.com.
About
Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue[2] fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.
If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a 'Priority Review Voucher' at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.
Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.
Visit www.islandpharmaceuticals.com for more on Island.
(C) 2022 Electronic News Publishing, source